MicroPoint Bioscience

MicroPoint Bioscience, founded in 2007 by Nan Zhang, operates as a global provider of point-of-care testing (POCT) systems and solutions. The company is headquartered in Shenzhen, China, with U.S. operations based in Santa Clara, California. Micropoint has secured $58.7 million in funding from 12 investors, including notable firms like Qiming Venture Partners, Northern Light Venture Capital, and Atinum Investment.

The core of Micropoint's business is the development, manufacturing, and marketing of 'Lab-on-a-Chip' products that utilize microfluidic and Micro-Electro-Mechanical Systems (MEMS) technology. This allows for the creation of rapid diagnostic tools that require minimal sample volumes to deliver results within minutes. The company serves medical professionals and patients through a distribution network of over 100 partners worldwide, providing tools for use at the bedside, in hospitals, or at home. Its business model centers on the sale of these diagnostic instruments and the accompanying disposable testing cartridges.

Micropoint's product portfolio is structured around two main platforms: mLabs® and qLabs®. The mLabs® platform uses microfluidic immunofluorescence for highly sensitive detection of markers for cardiovascular diseases, inflammation, diabetes, and fertility. The qLabs® platform focuses on electrochemistry to provide rapid blood coagulation tests, such as PT/INR and APTT, for patients on anticoagulant therapy and for veterinary use. The company has received CE marking and NMPA certification for its platforms and its manufacturing facilities in both China and the U.S. are ISO 13485 certified.

Keywords: point-of-care testing, POCT, microfluidics, Lab-on-a-Chip, MEMS, in-vitro diagnostics, coagulation monitoring, cardiac markers, immunofluorescence, electrochemistry, diagnostic equipment, medical devices, rapid diagnostics, self-testing, cardiovascular diagnostics, anticoagulant therapy, portable analyzers, immunoassay, diagnostic cartridges, veterinary diagnostics